Lv11
66 积分 2022-11-15 加入
RET fusion rather than BRAF mutation confers a higher risk of aggressiveness and recurrence in papillary thyroid carcinoma
1小时前
待确认
Neoadjuvant Combination Therapy with Tyrosine Kinase and Immune Checkpoint Inhibitors in Anaplastic Thyroid Cancer: A Single-Center, Real-World Experience
1个月前
已完结
Small-cell lung cancer: anatomy of an immune-cold tumor
1个月前
已完结
Toripalimab vs Dacarbazine as First-Line Therapy for Advanced Melanoma of Acral Subtype
2个月前
已完结
Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study
2个月前
已完结
Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial
2个月前
已完结
Artificial intelligence-enabled ultrasound diagnosis and stratification of follicular thyroid neoplasms: a multi-center study
2个月前
已完结
Thyroid cancer in Asia: incidence, mortality in 2022, and future projections to 2050
2个月前
已完结
The 2025 ATA guidelines for differentiated thyroid Cancer - Ten years of professional debate and measured progress
2个月前
已完结
Artificial intelligence-enabled ultrasound diagnosis and stratification of follicular thyroid neoplasms: a multi-center study
2个月前
已完结
皖公网安备34019202002308
